Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer
Not yet recruiting · NCT06700603 · Registry updated 2024-11-22Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Not yet recruiting | Phase 2 | 2024-11-22 | NCT06700603 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Rui-hua Xu, MD, PhD | 3 |
0 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| No products are listed yet. | |||